http:\/\/conitec.gov.br\/consultas-publicas<\/a>.<\/p>\n
\nRefer\u00eancias:
\n[1] Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med. 2002;2(2):145-66.
\n[2] Kishnani PS, Hwu WL, Mandel H, et al.; Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671-676.
\n[3] MalaCards. MalaCards Human Disease Database [Available from: https:\/\/www.malacards.org\/card\/glycogen_storage_disease_ii#genetic_variations.
\n[4] Hirschhorn R, Reuser AJJ. Glycogen Storage Disease Type II: Acid Alphaglucosidase (Acid Maltase) Deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle MD (Eds). The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001: 3389-3420.
\n[5] van der Beek NA, de Vries JM, Hagemans ML, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis. 2012;7:88.
\n[6] Wens SC, Ciet P, Perez-Rovira A, et al. Lung MRI and impairment of diaphragmatic function in Pompe dis\u00acease. BMC Pulm Med. 2015;15:54.
\n[7] Kassardjian CD, Engel AG, Sorenson EJ. Electromyographic findings in 37 patients with adult-onset acid maltase deficiency. Muscle Nerve. 2015;51(5):759-61.
\n[8] Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99-109.
\n[9] Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329-35.<\/p>\n","protected":false},"excerpt":{"rendered":"
A Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS (CONITEC) abriu a consulta p\u00fablica n\u00ba 33 – Alfa-Alglicosidase Para Doen\u00e7a de Pompe – at\u00e9 24 de junho, com o objetivo de definir o protocolo cl\u00ednico e a diretriz terap\u00eautica para a Doen\u00e7a de Pompe. A Doen\u00e7a de Pompe (DP) \u00e9 uma doen\u00e7a gen\u00e9tica,…<\/p>\n","protected":false},"author":7,"featured_media":12932,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ngg_post_thumbnail":0,"footnotes":""},"categories":[37],"tags":[704,706,707,234,703,708,233],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2025-07-07 18:00:26","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts\/12951"}],"collection":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/comments?post=12951"}],"version-history":[{"count":6,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts\/12951\/revisions"}],"predecessor-version":[{"id":12973,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts\/12951\/revisions\/12973"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/media\/12932"}],"wp:attachment":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/media?parent=12951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/categories?post=12951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/tags?post=12951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}